ArticleMedicine2026
A cross-sectional analysis and forward projection of China's gallbladder and biliary-tract cancer burden: Insights from the 2021 Global Burden of Disease Study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder and biliary tract cancer (GBTC) remains highly lethal. We examined 32-year epidemiological trends in China and projected outcomes to 2050. Using 2021 Global Burden of Disease (GBD) data, we extracted annual GBTC incident and prevalent cases, deaths, and disability-adjusted life years (DALYs) for 1990 to 2021, stratified by sex, age, and socio-demographic index (SDI). The age-standardized rates (ASRs) were calculated, and ARIMA models forecast 2050 incidence and mortality. Globally, GBTC risk rises after age 60 and correlates with SDI (R = 0.588). In China, cases increased from 17,077 in 1990 to 51,720 in 2021, raising the age-standardized incidence rate (ASIR) from 2.04 to 2.49/100,000 (+0.50% annually). Prevalent cases increased to 79,688 (age-standardized prevalence rate (ASPR) 3.77/100,000). Conversely, ASMR fell from 2.32 to 1.85/100,000 (-0.75%), and DALYs declined from 51.3 to 40.4/100,000 (-0.87%), driven by fewer years of life lost (YLL). Males drove incidence and prevalence. Projections suggest male incidence will keep rising until 2050, while female rates are projected to plateau; male mortality stays stable, and female mortality continues a gradual decline. Aging and rising SDI inflate GBTC incidence, yet improved care compresses mortality. Males carry an increasing share. Targeted prevention and early detection are critical to curb incidence and improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.